90 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
XLRN Acceleron Pharma Inc. $52 $2.39B N/A
Article Searches
Acceleron Pharma (XLRN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release http://www.zacks.com/stock/news/775514/acceleron-pharma-xlrn-may-report-negative-earnings-know-the-trend-ahead-of-next-weeks-release?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-775514 Feb 20, 2020 - Acceleron (XLRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2 Top Biotech Stocks to Buy Right Now https://www.fool.com/investing/2020/02/10/2-top-biotech-stocks-to-buy-right-now.aspx?source=iedfolrf0000001 Feb 10, 2020 - These companies could crush the broader markets this year.
Factors Setting the Tone for Bristol-Myers (BMY) Q4 Earnings http://www.zacks.com/stock/news/746879/factors-setting-the-tone-for-bristol-myers-bmy-q4-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-746879 Feb 03, 2020 - Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports fourth-quarter results.
Biotech Stock Roundup: EPZM Drug Gets FDA Nod, XLRN & HEPA Surge on Study Data http://www.zacks.com/stock/news/738803/biotech-stock-roundup-epzm-drug-gets-fda-nod-xlrn-hepa-surge-on-study-data?cid=CS-ZC-FT-analyst_blog|stock_roundup-738803 Jan 29, 2020 - It has been a busy week for the biotech sector with pipeline and regulatory updates from quite a few players.
Acceleron (XLRN) Up on Success of PAH Drug in Phase II Study http://www.zacks.com/stock/news/737359/acceleron-xlrn-up-on-success-of-pah-drug-in-phase-ii-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-737359 Jan 28, 2020 - Acceleron (XLRN) stock surges as sotatercept meets primary and secondary endpoints in a phase II study in patients with pulmonary arterial hypertension.
Acceleron, Fulcrum Therapeutics Ink Deal for Pulmonary Disease http://www.zacks.com/stock/news/696154/acceleron-fulcrum-therapeutics-ink-deal-for-pulmonary-disease?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-696154 Dec 31, 2019 - Acceleron (XLRN) signs a collaboration/license pact with Fulcrum Therapeutics aimed at identifying small molecules designed to modulate specific pathways targeting a pulmonary disease indication.
Agios' Tibsovo Wins FDA's Breakthrough Therapy Tag for MDS http://www.zacks.com/stock/news/675019/agios-tibsovo-wins-fdas-breakthrough-therapy-tag-for-mds?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-675019 Dec 17, 2019 - The FDA bestows a Breakthrough Therapy status on Agios' (AGIO) leukemia drug Tibsovo for treating relapsed/refractory myelodysplastic syndrome in adult patients with a susceptible IDH1 mutation.
Acceleron Pharma (XLRN) Presents At 2019 ASH Annual Meeting - Slideshow https://seekingalpha.com/article/4311927-acceleron-pharma-xlrn-presents-2019-ash-annual-meeting-slideshow?source=feed_sector_healthcare Dec 11, 2019 - The following slide deck was published by Acceleron Pharma Inc. in conjunction with this event.
Bristol-Myers' (BMY) Lymphoma Drug Meets Goals in Key Study http://www.zacks.com/stock/news/662000/bristol-myers-bmy-lymphoma-drug-meets-goals-in-key-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-662000 Dec 09, 2019 - Bristol-Myers' (BMY) TRANSCEND NHL 001 study on CAR T-cell therapy drug meets endpoints.
Biotech Stock Roundup: SLDB Plunges, CELG Gets FDA Nod for Reblozyl & Other Updates http://www.zacks.com/stock/news/618288/biotech-stock-roundup-sldb-plunges-celg-gets-fda-nod-for-reblozyl-other-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-618288 Nov 13, 2019 - Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.

Pages: 123456...9

Page 1>